Biomarkers in peripheral arterial disease patients and near- and longer-term mortality.
BACKGROUND
Whether novel biomarkers improve risk prediction of mortality beyond standard cardiovascular disease (CVD) risk markers in peripheral arterial disease (PAD) patients, and whether any such prediction differs with length of follow-up, remains controversial. Our objective was to determine in patients with PAD whether novel biomarkers improve prediction of CVD mortality and total mortality.


METHODS
A cohort of 397 patients who were referred to a vascular lab had PAD diagnosed by noninvasive testing. Fifty-eight percent also had coronary or cerebrovascular disease at baseline. Predictors of total, CVD, and non-CVD mortality were assessed with Cox proportional hazards models, and the incremental value of predictors was evaluated with both the C-statistic and the integrated discrimination improvement (IDI) index.


RESULTS
Total mortality was 11% at 2-year follow-up and 65% at an average of 6.6-year of follow-up (maximum, 11.4 years). At 2 years, hs-CRP was a strong and significant predictor of mortality, with a hazard ratio (HR) of 1.56 per standard deviation (P = .006). However, at full follow up, standard CVD risk markers were significant (age, gender, ankle-brachial index, other CVD, and hypertension), but hs-CRP no longer showed a significant relationship (HR 1.12; P = .11). None of the other biomarkers studied showed a significant independent association with mortality. Hs-CRP improved the C-statistic and the IDI beyond standard risk markers at 2 years, but not at full follow-up.


CONCLUSIONS
hs-CRP was a strong predictor of short-term mortality in this cohort of PAD patients, while standard risk markers were better at predicting longer-term mortality.
Criqui
Michael H
MH
University of California San Diego School of Medicine, La Jolla, CA 92093-0607, USA. mcriqui@ucsd.edu
Ho
Lindsey A
LA
Denenberg
Julie O
JO
Ridker
Paul M
PM
Wassel
Christina L
CL
McDermott
Mary M
MM
D000367:Age Factors; D000368:Aged; D055109:Ankle Brachial Index; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000097:blood* / Q000401:mortality*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D006973:Hypertension / Q000401:mortality; D053208:Kaplan-Meier Estimate; D008297:Male; D016491:Peripheral Vascular Diseases / Q000097:blood* / Q000401:mortality*; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D018570:Risk Assessment; D012307:Risk Factors; D012737:Sex Factors; D013997:Time Factors
D015415:Biomarkers; D002097:C-Reactive Protein
Arch Intern Med. 2001 Nov 12;161(20):2474-80
11700160
Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):493-8
10073948
Circulation. 2007 Feb 20;115(7):928-35
17309939
N Engl J Med. 2006 Dec 21;355(25):2615-7
17182986
Circulation. 2007 Apr 24;115(16):2119-27
17404162
J Am Coll Cardiol. 2007 Jun 5;49(22):2172-81
17543637
Clin Chem. 2008 Feb;54(2):234-7
18223130
J Vasc Surg. 2007 Sep;46(3):500-6
17681710
Am J Epidemiol. 2007 Mar 15;165(6):684-95
17215383
JAMA. 2005 Jul 20;294(3):326-33
16030277
Circulation. 2006 May 9;113(18):2177-85
16651468
N Engl J Med. 2006 Dec 21;355(25):2631-9
17182988
Ann Intern Med. 2008 Jan 15;148(2):85-93
18195333
Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1121-7
9194763
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12
17569110
JAMA. 2009 Jul 1;302(1):37-48
19567438
J Am Coll Cardiol. 2004 Aug 4;44(3):618-23
15358030
N Engl J Med. 2004 Apr 1;350(14):1387-97
15070788
Vasc Med. 1999;4(1):15-21
10355865
Ann Intern Med. 2006 Jul 4;145(1):21-9
16818925
N Engl J Med. 2008 May 15;358(20):2107-16
18480203
N Engl J Med. 1992 Feb 6;326(6):381-6
1729621
J Clin Epidemiol. 2002 May;55(5):445-51
12007546
JAMA. 2007 Feb 14;297(6):611-9
17299196